Cargando…

Safety and efficacy of GEMOX plus donafenib and tislelizumab as first‐line therapy for advanced epithelial malignant biliary tract cancer

AIM: This study was aimed to evaluate the safety and the efficacy of gemcitabine and oxaliplatin (GEMOX) combined with donafenib plus tislelizumab as the first‐line treatment for patients with unresectable biliary tract cancer (BTC). METHODS: This is a prospective single‐center exploratory study. El...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Longrong, Zhang, Ning, Wang, Yixiu, Zhang, Ti, Zhu, Weiping, Mao, Anrong, Zhao, Yiming, Wang, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278481/ https://www.ncbi.nlm.nih.gov/pubmed/37039263 http://dx.doi.org/10.1002/cam4.5924

Ejemplares similares

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial
por: Liu, Qiu-Ping, et al.
Publicado: (2023)

TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial
por: Qi, Weili, et al.
Publicado: (2023)

Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study
por: Wang, Kang, et al.
Publicado: (2023)

EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs
por: Cai, Wen, et al.
Publicado: (2018)

Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer
por: Lagenfelt, Hanna, et al.
Publicado: (2021)

RNA sequencing analysis reveals the competing endogenous RNAs interplay in resected hepatocellular carcinoma patients who received interferon-alpha therapy
por: Wu, Yibin, et al.
Publicado: (2021)

Donafenib treatment for hepatocellular carcinoma: A case report
por: Li, Qiaoqi, et al.
Publicado: (2021)

The Value of Laparoscopic Simultaneous Colorectal and Hepatic Resection for Synchronous Colorectal Cancer Liver Metastasis: A Propensity Score Matching Study
por: Zhou, Jiamin, et al.
Publicado: (2022)

Enhanced Recovery After Surgery in Patients With Hepatocellular Carcinoma Undergoing Laparoscopic Hepatectomy
por: Zhou, Jiamin, et al.
Publicado: (2021)

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
por: Wang, Zhixin, et al.
Publicado: (2022)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

Donafenib and GSK‐J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression
por: Zheng, Chenyang, et al.
Publicado: (2023)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study
por: Passardi, Alessandro, et al.
Publicado: (2019)

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
por: Quan, Qi, et al.
Publicado: (2020)

Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience
por: Wang, Longrong, et al.
Publicado: (2020)

Partial response of donafenib as the third-line therapy in metastatic colon cancer: A case report
por: Yang, Yang, et al.
Publicado: (2021)

Imaging of malignancies of the biliary tract- an update
por: Hennedige, Tiffany Priyanthi, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
por: Chen, Ruijia, et al.
Publicado: (2022)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
por: Meng, Rui, et al.
Publicado: (2022)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
por: Pei, Zhengda, et al.
Publicado: (2023)

Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
por: Assenat, Eric, et al.
Publicado: (2019)

Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies
por: Passardi, Alessandro, et al.
Publicado: (2021)

Percutaneous transhepatic and endoscopic biliary drainage for malignant biliary tract obstruction: a meta-analysis
por: Leng, Jian-jun, et al.
Publicado: (2014)

The Clinical Benefit of Percutaneous Transhepatic Biliary Drainage for Malignant Biliary Tract Obstruction
por: Nikolić, Ivan, et al.
Publicado: (2022)

Donafenib-Loaded Callispheres Beads Embolization in a VX2 Liver Tumor: Investigating Efficacy, Safety, and Improvement of Tumor Angiogenesis After Embolization
por: Li, Tongqiang, et al.
Publicado: (2021)

Successful Outcome of Programmed Death 1 Blockade Plus GemOx for Epstein-Barr Virus-Associated Primary Nodal T/NK Cell Lymphoma: A Case Report
por: Xia, Liang, et al.
Publicado: (2021)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
por: Zhou, Chongchong, et al.
Publicado: (2023)

Worldwide trends in mortality from biliary tract malignancies
por: Patel, Tushar
Publicado: (2002)

Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma
por: Paule, Bernard, et al.
Publicado: (2010)

Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8(+) T-Cell Infiltration in Rabbit VX2 Liver Tumor
por: Shi, Qin, et al.
Publicado: (2021)

Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study
por: Ren, Xiang, et al.
Publicado: (2022)

Monoacylglycerol lipase promotes progression of hepatocellular carcinoma via NF-κB-mediated epithelial-mesenchymal transition
por: Zhu, Weiping, et al.
Publicado: (2016)

Horizons on the Therapy of Biliary Tract Cancers: A State-of-the-art Review
por: Xue, Ran, et al.
Publicado: (2021)

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report
por: Ding, Xiao-Sheng, et al.
Publicado: (2021)

Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report
por: Yang, Rui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1u2ul7rm4cl4ci40kjnl7o1hvv